论文部分内容阅读
目的:探讨左乙拉西坦(Lev)添加剂量治疗难治性癫癎的疗效和安全性。方法:采用开放性自身对照方法,对48例(儿童23例,成人25例)难治性癫癎患者进行Lev添加治疗,并随访1年以上,收集治疗后患者发作频率变化、无发作情况、不良反应以及退出原因。结果:Lev治疗难治性癫癎总有效率为64.58%,成人有效率高于儿童,对部分性癫癎综合征有效率高;3、6和12个月无发作率分别为6.25%、18.75%和16.67%,保留率为81.25%、56.25%和43.75%。总不良反应发生率为39.58%,无严重不良反应,退出的最主要原因为对疗效欠满意。结论:LEV是一种安全有效的难治性癫癎治疗药物,对部分性和全面性癫癎发作均有效。
Objective: To investigate the efficacy and safety of levofibrate (Lev) in the treatment of refractory epilepsy. Methods: 48 patients (23 children and 25 adults) with refractory epilepsy were treated with Lev supplemented by open self-control method. The patients were followed up for more than 1 year. The frequency of seizure and the absence of seizure were collected. Adverse reactions and reasons for withdrawal. Results: The total effective rate of Lev in the treatment of refractory epilepsy was 64.58%. The effective rate of adults was higher than that of children, and the effective rate was high in partial epilepsy syndrome. The unresponsive rates of 3, 6 and 12 months were 6.25% and 18.75 % And 16.67% respectively, with retention rates of 81.25%, 56.25% and 43.75%. The total incidence of adverse reactions was 39.58%, no serious adverse reactions, the main reason for the withdrawal of the less satisfied with the efficacy. Conclusion: LEV is a safe and effective treatment for refractory epilepsy, which is effective in partial and complete epileptic seizures.